Opportunities Beyond Pharma in the COVID-19 Vaccine Race
COVID-19, Feature, FinanceSayeed Yousuf Ahmedmcgill business review, mcgill, desautels, desautels faculty of management, MUS, tech & innovation, finance & markets, global news & politics, pharma, big pharma, vaccinology, vaccine, COVID-19, Coronavirus, sayeed yousuf ahmed, Pfizer, Moderna, AstraZeneca, FDA approval, pandemic, World Health Organization, Oxford, biotech, R&D, stock market
The Antibiotics Market is Broken – Can We Fix it?
Editors Choice, TechClara MacMahonmcgill business review, mcgill, desautels, desautels faculty of management, MUS, tech & innovation, finance & markets, global news & politics, antibiotics, big pharma, pharma, healthcare, public health, Clara MacMahon, Science and Sustainability
Universal Pharmacare: A Tough Pill to Swallow
Editors Choice, FinanceSarah Thomasmcgill business review, mcgill, desautels, desautels faculty of management, MUS, tech & innovation, finance & markets, global news & politics, Sarah Thomas, healthcare, public health, pharma, Canada, Economy & Markets 2.0
Can the healthcare sector boost your portfolio’s immune system in 2019?
FinanceSarah Thomasmcgill business review, mcgill, desautels, desautels faculty of management, MUS, tech & innovation, finance & markets, global news & politics, Sarah Thomas, healthcare, public health, stock market, Mutual Funds, NYSE, pharma, Economy & Markets 2.0
